GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Betty Lawrence
Angiochem Inc
Study Director - Nancy Lin, MD
Dana-Farber Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ingalls Memorial Hospital
Harvey, Illinois, United States
- Nci
Rockville, Maryland, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2011
- Primary completion
- 30 Jun 2015
- Completion
- 31 Oct 2015
- Last update posted
- 13 Jul 2016
- Registered enrollment
- 85
- Registry id
- NCT01480583
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.